Fundraising Fox

Cybin

NASDAQ: HELP

Toronto · Founded 2019 · Ontario, Canada corporation · 3 known investors

cybin.com ↗

Helus Pharma (branded Cybin) is a clinical-stage biotech developing novel serotonergic agonist therapies for mental health conditions, with lead programs including CYB004 in Phase 2 trials for generalized anxiety disorder. The company builds proprietary drug development and delivery formulations aimed at treating psychiatric disorders.

BiotechDigital HealthMental Health

Founders & leadership

Cybin was founded in 2019 by Eric So and Paul Glavine.

ESEric So
Eric SoCo-Founder, Executive Chairman & Interim CEO
PG
Paul GlavineCo-founder
GF
Gabriel FahelExecutive
GT
George TzirasExecutive
AB
Aaron BartloneExecutive
GC
Greg CaversExecutive
DD
Douglas DrysdaleExecutive
AIAmir Inamdar
Amir InamdarChief Medical Officer
JP
Jacqueline PoriadjianExecutive
JK
John KanakisExecutive
AN
Alex NivorozhkinChief Scientific Officer
KJ
Kanakis JohnNamed on SEC filing

Investors · 3

Innovating CapitalNew York · $10K – $3M
JLSNew York
NoeticToronto

Reported raises · per SEC filings

Form D private placements

$218M disclosed across 10 of 31 rounds · 2020–2026

▶Undisclosed amountofferedAug 2026 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SoExecutive Officer, Director
  • Michael HalsteadExecutive Officer
  • Greg CaversExecutive Officer
  • Paul GlavineExecutive Officer, Director
  • Gabriel FahelExecutive Officer
  • Alex NivorozhkinExecutive Officer
  • Aaron BartloneExecutive Officer
  • George TzirasExecutive Officer
  • Amir InamdarExecutive Officer
  • Theresa FirestoneDirector
  • Mark LawsonDirector
  • Grant FroeseDirector
  • Eric HoskinsDirector
  • Freda Lewis-HallDirector
First sale
Aug 2026
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedAug 2026 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SoExecutive Officer, Director
  • Michael HalsteadExecutive Officer
  • Greg CaversExecutive Officer
  • Paul GlavineExecutive Officer, Director
  • Gabriel FahelExecutive Officer
  • Alex NivorozhkinExecutive Officer
  • Aaron BartloneExecutive Officer
  • George TzirasExecutive Officer
  • Amir InamdarExecutive Officer
  • Theresa FirestoneDirector
  • Mark LawsonDirector
  • Grant FroeseDirector
  • Eric HoskinsDirector
  • Freda Lewis-HallDirector
First sale
Aug 2026
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$511.7KofferedJul 2026 · 13 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SoExecutive Officer, Director
  • George TzirasExecutive Officer
  • Gabriel FahelExecutive Officer
  • Paul GlavineExecutive Officer, Director
  • Greg CaversExecutive Officer
  • Aaron BartloneExecutive Officer
  • Amir InamdarExecutive Officer
  • Theresa FirestoneDirector
  • Mark LawsonDirector
  • Grant FroeseDirector
  • Eric HoskinsDirector
  • Freda Lewis-HallDirector
Offering amount
$511.7K
First sale
Jul 2026
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedJul 2026 · 5 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SoExecutive Officer, Director
  • George TzirasExecutive Officer
  • Gabriel FahelExecutive Officer
  • Paul GlavineExecutive Officer, Director
  • Greg CaversExecutive Officer
  • Aaron BartloneExecutive Officer
  • Amir InamdarExecutive Officer
  • Theresa FirestoneDirector
  • Mark LawsonDirector
  • Grant FroeseDirector
  • Eric HoskinsDirector
  • Freda Lewis-HallDirector
First sale
Jul 2026
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedMar 2026 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Theresa FirestoneDirector
  • Gabriel FahelExecutive Officer
  • Mark LawsonDirector
  • Grant FroeseDirector
  • George TzirasExecutive Officer
  • Paul GlavineDirector, Executive Officer
  • Michael ColaExecutive Officer
  • Eric HoskinsDirector
  • Eric SoDirector, Executive Officer
  • Greg CaversExecutive Officer
  • Aaron BartloneExecutive Officer
First sale
Mar 2026
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$114.2KofferedJan 2026 · 3 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric HoskinsDirector
  • Theresa FirestoneDirector
  • Gabriel FahelExecutive Officer
  • Aaron BartloneExecutive Officer
  • Greg CaversExecutive Officer
  • Grant FroeseDirector
  • Eric SoDirector, Executive Officer
  • Paul GlavineDirector, Executive Officer
  • George TzirasExecutive Officer
  • Mark LawsonDirector
Offering amount
$114.2K
First sale
Dec 2025
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$288.6KofferedNov 2025 · 5 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SoDirector, Executive Officer
  • Aaron BartloneExecutive Officer
  • Eric HoskinsDirector
  • George TzirasExecutive Officer
  • Greg CaversExecutive Officer
  • Mark LawsonDirector
  • Theresa FirestoneDirector
  • Paul GlavineDirector, Executive Officer
  • Gabriel FahelExecutive Officer
  • Grant FroeseDirector
Offering amount
$288.6K
First sale
Nov 2025
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$601.9KofferedOct 2025 · 4 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Gabriel FahelExecutive Officer
  • Mark LawsonDirector
  • Paul GlavineDirector, Executive Officer
  • Grant FroeseDirector
  • Greg CaversExecutive Officer
  • Aaron BartloneExecutive Officer
  • George TzirasExecutive Officer
  • Eric SoDirector, Executive Officer
  • Theresa FirestoneDirector
  • Eric HoskinsDirector
Offering amount
$601.9K
First sale
Oct 2025
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Cybin do?
Helus Pharma (branded Cybin) is a clinical-stage biotech developing novel serotonergic agonist therapies for mental health conditions, with lead programs including CYB004 in Phase 2 trials for generalized anxiety disorder. The company builds proprietary drug development and delivery formulations aimed at treating psychiatric disorders.
Who founded Cybin?
Cybin was founded by Eric So, Paul Glavine in 2019.
Who are Cybin's investors?
Cybin's investors include Innovating Capital, JLS, Noetic.
How much funding has Cybin raised?
Cybin has disclosed $218M raised across 10 of its 31 known rounds.
Where is Cybin headquartered?
Cybin is headquartered in Toronto.